Business Wire
13 Sept 2026, 11:00 UTC · 6h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
1 claim · each scored for market impact
Summit Therapeutics' partner Akeso will present updated Phase III HARMONi-2 trial data, including overall survival (OS), for ivonescimab at the WCLC 2026 conference. — Overall survival data in a Phase III trial is a primary clinical endpoint that can significantly drive valuation for biotech firms like SMMT.
+0.50Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
[mutual] Summit Therapeutics is partners with Akeso Inc. regarding the investigational antibody ivonescimab.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
10h ago
